We report in silico identification and characterisation of a novel member of the ras association domain family 1 (RASSF1)/NORE1 family, namely, RASSF2, located at chromosomal region 20p13. It has three isoforms, all contain a ras association domain in the C-terminus. The longest isoform RASSF2A contains a 5 0 CpG island. RASSF2A was cloned from a brain cDNA library and directly sequenced, confirming the genomic gene structure. In previous reports, we and others have demonstrated that RASSF1A is epigenetically inactivated in a variety of cancers, including sporadic colorectal cancer (CRC). In the present report, we analysed the methylation status of RASSF2A promoter region CpG island in sporadic CRC and compared it to K-ras mutation status. RASSF2A promoter region CpG island was hypermethylated in a majority of colorectal tumour cell lines (89%) and in primary colorectal tumours (70%), while DNA from matched normal mucosa was found to be unmethylated (tumour-specific methylation). RASSF2A expression was reactivated in methylated tumour cell lines after treatment with 5-aza 2-deoxycytidine. RASSF2A methylation is an early event, detectable in 7/8 colon adenomas. Furthermore, 75% of colorectal tumours with RASSF2A methylation had no K-ras mutations (codons, 12 and 13) (P ¼ 0.048), Fisher's exact test). Our data demonstrate that RASSF2A is frequently inactivated in CRCs by CpG island promoter hypermethylation, and that epigenetic (RASSF2A) and genetic (K-ras) changes are mutually exclusive and provide alternative pathways for affecting Ras signalling.
Introduction
We and others have recently identified a novel gene, ras association domain family 1 (RASSF1) (reviewed in Agathanggelou et al., 2005) . The two main isoforms A and C are well expressed in normal tissues; however, expression of RASSF1A but not RASSF1C is lost in a majority of human cancers (Dammann et al., 2000; Lerman and Minna, 2000; Agathanggelou et al., 2001) . This loss of expression correlates with hypermethylation of a promoter CpG island. Both A and C isoforms contain a ras association domain in the carboxy terminus, in addition RASSF1A contains a DAGbinding domain at the N-terminus as well as an ATM phosphorylation site consensus sequence. Cells expressing exogenous RASSF1A have been shown to suppress tumorigenicity in nude mice, reduce colony formation and suppress anchorage-independent growth (Dammann et al., 2000; Burbee et al., 2001; Dreijerink et al., 2001) . RASSF1 has homology to a known mammalian ras effector nore1 (Vavvas et al., 1998) . RASSF1A is brought into the ras signalling pathway by heterodimerization with NORE1 (Ortiz-Vega et al., 2002) . RASS-F1A is thought to be involved in cell cycle regulation, apoptosis and microtubule stability Shivakumar et al., 2002; Agathanggelou et al., 2003; Liu et al., 2003; Dallol et al., 2004; Vos et al., 2004) . We have used in silico approaches to identify further members of the RASSF family. In a previous report, we demonstrated that NORE1A like RASSF1A is hypermethylated in a subset of non-small-cell lung carcinomas (NSCLCs). More recently, Irimia et al. (2004) have confirmed these results and have shown that in NSCLC, NORE1A hypermethylation inversely correlates with K-ras mutations. We also identified and characterised another member of the RASSF gene family, AD037, located at 10q11.21 (Eckfeld et al., 2004) . The AD037 5 0 CpG island is hypermethylated in lung and breast tumours and this hypermethylation correlates with loss of gene expression. AD037 binds directly to activated Ras in a GTP-dependent manner. Exogenous expression induces ras-dependent apoptosis and inhibits growth of human tumour cell lines. In this report, we characterised another member of the RASSF family, RASSF2, and demonstrate that a CpG island located in the promoter region of RASSF2A is frequently hypermethylated in colorectal tumours, and the hypermethylation inversely correlates with K-ras mutations in these tumours. While this work was in progress, Vos et al. (2003) independently identified RASSF2 as a novel ras effector. However, this is the first report describing epigenetic inactivation of the RASSF2A gene in human cancer.
Results
In silico characterisation and cloning of RASSF2 Using bioinformatics analysis, three isoforms of the RASSF2 gene located at 20p13 were identified as RASSF1 homologues (Figure 1a ). RASSF2A, RASSF2B and RASSF2C all contain predicted rasassociation (RA) domains, although RASSF2B mRNA produces a much shorter protein with a truncated RA domain. RASSF2A and RASSF2C contain a C-terminal coiled-coil SARAH domain that is absent in RASSF2B. Figure 1a . Comparisons of sequence homology with RASSF1A show that these proteins share 14% amino-acid identity over their entire lengths and 23% identity over their RA domains. The greater degree of homology over the RA domain again indicates functional conservation of this sequence. BLAST database searches of the proteomes of other species identified orthologues in the mouse, rat and cow, all known as Rassf2. The protein identified in Bos Taurus, however, did not encode a predicted RA domain; therefore, it remains to be determined whether this represents a true RASSF2 orthologue. The orthologues identified in mouse and rat, however, were highly similar to human RASSF2A, both sharing 92% amino acid identity over their entire lengths (Figure 1b ).
RASSF2 CpG island methylation analysis in colorectal tumours
Using combined bisulphite restriction analysis (COBRA) and bisulphite sequencing, the methylation status of the predicted promoter region CpG island was examined in colorectal tumour cell lines. Methylation was observed in 8/9 (89%) colorectal tumour cell lines (Figure 2a ). Direct sequencing showed dense methylation spanning the entire region analysed (Figure 2b ). RASSF2A CpG island hypermethylation corresponded with loss of RASSF2A expression in colorectal tumour cell lines. Furthermore, treatment of colorectal tumour cell lines with the demethylating agent 5-aza-2-deoxycytidine (5azaDC) reactivated RASSF2A expression (Figure 2c ), showing that promoter hypermethylation is the cause of inactivation of RASSF2A. Next, a methylated-specific PCR (MSP) assay was developed and used to determine whether methylation of the RASSF2A CpG island occurs in colorectal primary tumours ( Figure 3a) . Methylation was observed in 21/30 (70%) tumours. Moreover, this methylation was always tumour-specific ( Figure 3a ) and was not detected in the matched patient's DNA from normal mucosa (taken >10 cm from the primary). Thus, RASSF2A methylation arose in these patient's tumours as part of, and during, the tumourigenic process. To determine the pattern and extent of methylation, COBRA PCR products from two methylated colorectal tumours and corresponding normal mucosa were cloned and sequenced. Figure 3b shows that RASSF2A promoter CpG island is hypermethylated in both tumours compared to corresponding normal mucosa samples. We did not find any correlation between patient sex, tumour stage, survival or site of tumour (for all P>0.05) and RASSF2A methylation; RASSF2A was more frequently methylated in patients of older age (0.025, t-test) (Table 1 shows all the clinicopathological details for the tumours analysed). Previously, we had The RASSF2 gene is located at 20p13, occupies 46 kb of genomic DNA (Àstrand) and encodes at least three different isoforms, RASSF2A (AY154470), RASSF2B (AY154471) and RASSF2C (AY154472). Transcription of the RASSF2A isoform begins within a CpG island that spans exons 1 and 2 (grey box) at À105 bp to þ 1745 bp relative to the transcription start site of AY154470. RASSF2B transcription begins at exon 1b in intron 5. Transcription of RASSF2C begins at exon 1g in intron 2 of the gene. RASSF2B and RASSF2C do not have 5 0 CpG islands or predicted promoter regions. Bottom panel: All proteins produced by the RASSF2 gene contain predicted RA domains within the C-termini; however, RASSF2B contains a truncated RA domain due to alternative splicing of exons 6, 7, 8, 9 and 10, which introduces a stop codon in exon 10. RASSF2A (NP_055552) is a 326 aa protein containing an RA domain and acidic coiled-coil SARAH domain. RASSF2B (AAN59976) is a 157 aa protein containing a truncated RA domain. RASSF2C protein is identical to RASSF2A. (B) Amino-acid sequence alignment of human RASSF2A and orthologues in the mouse and rat. Shaded areas represent Ras-association (RA) domains (in dark grey) and coiled-coil SARAH domains (in light grey). The figure illustrates the high degree of homology between these orthologues over the entire protein length. *Represents locations of amino acids identical in all proteins; : represents locations of amino acids that undergo conservative substitution; ? represents locations of amino acids that undergo semi-conservative substitution. Sequences were aligned using the ClustalW program (www.ebi.ac.uk). The genbank accession numbers for mouse and rat protein sequences are NP_780654 and XP_230543, respectively RASSF2 methylation, K-ras mutation and colorectal cancer LB Hesson et al demonstrated that NORE1A was methylated and silenced in a subset of NSCLC (Hesson et al., 2003) .
In this study, we found that NORE1A methylation was infrequent in colorectal cancers (CRCs) (1/6 colorectal tumour lines; 3/28 CRC tumours) and there was no association between RASSF2A and NORE1A methylation. While RASSF1A was methylated in 15% (5/33) of the colorectal samples, again no association was found between RASSF2A and RASSF1A methylation status. Methylation status of RASSF3 (located at 12q14.1) (Tommasi et al., 2002) , another member of the RASSF1 gene family, was also analysed in colorectal tumour cell MDYSHQTSLVPCGQDKYISKNELLLHLKTYNLYYEGQNLQLRHREEEDEFIVEGLLNISW 60 ***:**.:*:*******:.*.*************************************** R.norvegicus GLRRPIRLQMQDDHERIRPPPSSSSWHSGCNLGAQGTTLKPLTVPTVQISEVDMPVENME 120 M.musculus GLRRPIRLQMQDDHERIRPPPSSSSWHSGCNLGAQGTTLKPLTMPTVQISEVDMPVEGLE 120 H.sapiens GLRRPIRLQMQDDNERIRPPPSSSSWHSGCNLGAQGTTLKPLTVPKVQISEVDAPPEGDQ 120 *************:*****************************:*.******* * *. :
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K-ras mutation status
We also screened these colorectal tumour samples for K-ras mutations at codons 12 and 13. We found that 75% of colorectal tumours with RASSF2A methylation had wild-type K-ras and this was statistically significant (P ¼ 0.048) ( Table 1) .
Discussion
While this work was in progress, RASSF2 was identified independently by Vos et al. (2003) , and they demonstrated direct in vivo binding of RASSF2A to K-ras in a GTP-dependent manner in HEK-293-T cells, whereas only weak association with activated H-Ras was observed. Interaction occurred between the effector domain of K-ras and the RA domain of RASSF2A. Furthermore, exogenous expression of RASSF2A inhibited the growth of lung tumour cells, with enhanced growth inhibition in the presence of activated K-ras (Vos et al., 2003) . It seems likely therefore that RASSF2A is a K-ras-preferential effector that promotes Figure 4 Methylation status of the RASSF2 CpG island in early adenoma polyps. We examined early adenoma polyps using MSP to determine whether hypermethylation of the RASSF2 CpG island was an early event in CRC formation. Methylation of the RASSF2 CpG island was found in 7/8 cases. This methylation was polyp specific in all cases. M represents methylated-specific PCR; U represents unmethylated-specific PCR; P represents polyp; N represents corresponding normal rectal mucosa RASSF2 methylation, K-ras mutation and colorectal cancer LB Hesson et al growth antagonistic effects in a ras-dependent manner. K-ras is the most commonly constitutively activated ras gene in human cancer (Downward, 2003) and it has been suggested that K-ras may be particularly critical in cancer due to recruitment of specific growth inhibitory downstream effectors. The data described by Vos et al. (2003) suggest that RASSF2A may be one such effector and that its inactivation may be beneficial for tumour cell survival by reducing K-ras apoptotic signals. RASSF2A is thought to interact with MST1 Praskova et al., 2004) ; therefore, loss of RASSF2A expression in tumours may result in reduced MST1-mediated proapoptotic signals. A role for RASSF2A in apoptosis is supported by recent data showing growth inhibition of lung tumour cells by increased apoptosis and cell cycle arrest (Vos et al., 2003) .
The results of this study show that RASSF2A mRNA expression is lost or drastically downregulated in most colorectal tumour cell lines. Furthermore, expression was fully restored following treatment with a demethylating agent. In colorectal tumour cell lines lacking RASSF2A expression, the entire RASSF2A CpG island was heavily methylated. In colorectal tumours, frequent RASSF2A CpG island methylation was observed in a tumour-specific manner. This was shown using MSP, COBRA and bisulphite sequencing. Furthermore, we demonstrate that in a majority of colorectal tumours, RASSF2A methylation occurs in the context of wild-type k-ras. Recently, van Engeland et al. (2002) also reported inverse correlation between RASSF1A methylation and K-ras mutations in colorectal tumours. RASSF2A is more frequently methylated in colorectal tumours compared to RASSF1A or NORE1A methylation (70, 15-45, 11%, respectively) Wagner et al., 2002; and this report) . Our results indicate that epigenetic inactivation of RASSF2A, a ras effector, is one of the most frequent events in CRC and may lead to the development of novel therapies affecting the ras signalling pathway, and that further analysis of the protein product of the RASSF2 gene is warranted. Our recent yeast two-hybrid results indicate that RASSF2 associates with NORE1, MST1, RASSF3 and several novel proteins that are being investigated (Hesson and Latif, unpublished data) . CRC is one of the most frequently occurring cancers in the western world and early detection offers a way to reduce deaths by this cancer. Epigenetic changes in CRC have been widely reported (Suzuki et al. (2002) ; reviewed in Herman, 2002; Kondo and Issa, 2004) . A recent study demonstrated that a subset of genes methylated in colorectal tumours and matching faecal DNA may form a basis for early detection (Muller et al., 2004) . RASSF2A methylation is frequent and is tumour-specific in CRCs and may be occurring in early colon tumourigenesis. Hence, RASSF2A methylation may provide a molecular biomarker for early detection of CRC. Ongoing research in our and other laboratories will provide further insights into the feasibility of using RASSF2A methylation, with perhaps a combination of other sets of genes, to detect CRC at an early stage.
Materials and methods

Tumour samples
A total of nine colorectal tumour cell lines (SW48, DLD1, 174 T, LS411, LoVo, HAC7, HT29, SW60 and SW480), 33 primary CRCs and eight adenomas were used in this study. For CRCs and adenoma polyps, corresponding normal mucosa and normal rectal mucosa, respectively, were also available.
Sodium Bisulphite modification
Sodium Bisulphite modification was performed as described previously (Agathanggelou et al., 2001) . Briefly, 0.5-1.0 mg of genomic DNA was denatured in 0.3 M NaOH for 15 min at 371C. Unmethylated cytosine residues were then sulphonated by incubation in 3.12 M sodium bisulphite (pH 5.0) (Sigma) and 5 mM hydroquinone (Sigma) in a thermocycler (hybaid Omn-E) for 15 s at 991C and 15 min at 501C for 20 cycles. Sulphonated DNA was then recovered using the Wizard DNA cleanup system (Promega) according to the manufacturer's instructions. The DNA was desulphonated by addition of 0.3 M NaOH for 10 min at room temperature. The converted DNA was then ethanol precipitated and resuspended in 50 ml of water.
Combined bisulphite restriction analysis (COBRA) and Bisulphite sequencing
Colorectal tumour cell lines were assayed for RASSF2 CpG island hypermethylation using COBRA assay followed by direct sequencing to confirm methylation status and ascertain the extent of methylation. Seminested PCR (expression analysis and MSP) was performed on a GeneAmp 9700 thermocycler (Perkin-Elmer) and with HotStar Taq DNA polymerase (Qiagen). The primers and conditions used were as follows: initial denaturation for 10 min at 951C, followed by 30 cycles of 1 min at 941C, 1 min at 571C and 2 min at 741C with a final extension for 10 min at 721C using the primers RASSF2 F 5 0 -TTYGAAGAAAGTTGTGGTTTGGAGTTAGTT-3 0 and RASSF2 R 5 0 -TATCCCCAAAACTCTCCRACTTAAAAC TA-3 0 (where Y ¼ C or T and R ¼ A or G to allow unbiased PCR amplification with regard to methylation status). The reaction volume of 20 ml contained 40 ng bisulphite-modified DNA, 1.5 mM MgCl 2 , 0.25 mM dNTPs, 1 mM each primer and 0.5 U HotStar Taq DNA polymerase. A measure of 1 ml of this reaction was then used in a seminested PCR reaction (50 mls) using RASSF2 F (described above) and RASSF2 RN 5 0 -CCAAACTAAAATCCCAACRACCTCAAA-3 0 . The same PCR programme was used but with 1U HotStar Taq DNA polymerase and 0.4 mM each primer. This produced a 378 bp PCR product. PCR products were then assayed for methylation by incubation with TaqI and BstUI for 2 at 65 and 601C, respectively, before visualization on a 2% agarose gel with added ethidium bromide. PCR products were also purified using QIAquick PCR purification columns (Qiagen, according to the manufacturer's instructions), reamplified using an ABI BigDye Cycle Sequencing kit V2.0 (Perkin-Elmer) and analysed using an ABI Prism 3700 DNA sequencer (PerkinElmer). For primary tumours, PCR products were first cloned using the pGEM-T Easy Vector System II (Promega) and transformed into DH5a Escherichia Coli cells before isolation and sequencing of cloned PCR products.
MSP
The promoter methylation status of RASSF2 in CRCs, adenoma polyps and corresponding normal colorectal epi-thelium was determined using MSP. Primers were designed to amplify a region within a predicted promoter region at þ 772 to þ 979 bp relative to the transcription start point of NM_014737 (PromoterInspector at www.genomatix.de) located between the first two noncoding exons of the RASSF2A isoform. The region examined for methylation was also within a CpG island that encompasses the first two noncoding exons of RASSF2A at À105 to þ 1745 bp relative to the transcription start point of NM_014737 (CpGplot at www.ebi.ac.uk). This CpG island is 1.8 kb in length with an ObsExp of 0.97 and a percentage CG of 68.61% (CpGreport at www.ebi.ac.uk). Two sets of primers were used that distinguish between methylated and unmethylated DNA sequences. The conditions and primers were as follows: initial denaturation for 10 min at 951C, followed by 35 cycles of 30 s at 951C, 30 s at 581C (MSP) or 30 s at 541C (USP) and 30 s at 721C with a final extension for 10 min at 721C using the primers MSP F 5 0 -GTT CGTCGTCGTTTTTTAGGCG-3 0 and MSP R 5 0 -AAAAA CCAACGACCCCCGCG-3 0 (for methylated-specific PCR) and USP F 5 0 -AGTTTGTTGTTGTTTTTTAGGTGG-3 0 and USP R 5 0 -AAAAAACCAACAACCCCCACA-3 0 (for unmethylated-specific PCR). The reaction volume of 25ml contained 100 ng bisulphate-modified DNA, 1.5 mM MgCl 2 , 0.25 mM dNTPs, 0.6 mM each primer and 1.25U HotStar Taq (Qiagen). Products were visualized on a 2% agarose gel with added ethidium bromide.
RASSF1A, NORE1A and RASSF3 methylation analysis was carried out as described previously in Hesson et al. (2004) .
Cell lines and 5azaDC treatment
Colorectal tumour cell lines were routinely maintained in RPMI 1640 growth media (Invitrogen) supplemented with 10% FCS at 371C, 5% CO 2 . 5-10 Â 10 5 cells were plated and allowed 24 h growth before addition of 2.5 mM 5azaDC (Sigma) freshly prepared in ddH 2 0 and filter-sterilized. The medium (including 2.5 mM) was changed every day for 5 days. Controls without 5azaDC were cultured concomitantly in the same manner. RNA was prepared using the RNeasy kit (Qiagen) according to the manufacturer's instructions.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
We analysed the expression of the RASSF2A isoform in colorectal tumour cell lines by designing primers specific for exon 2 and exon 7 (RASSF2A). Primer sequences: EXON 2 f 5 0 -GCGCCTAGAAC GTGTTTTTC-3 0 ; EXON 7 R 5 0 -ACTAGGCGTCCTCAC ATTGC-3 0 . In all, 1 mg of cDNA was first created using the SuperScript III cDNA synthesis kit (Invitrogen), 50 ng of cDNA was then analysed by PCR, which consisted of an initial denaturation of 10 min at 951C followed by 35 cycles of 951C for 30, 581C for 30 s, 721C for 30 s and a final extension of 10 min at 721C. The PCR reaction also required 3.0 mM MgCl 2 , 0.25 mM dNTPs, 0.8 mM each primer and 1 U HotStar Taq DNA polymerase. This produced a 563 bp product for RASSF2A. Primers used for the GAPDH control were 5 0 -TGAAGGTCGGAGTCAA CGGATTTGGT-3 0 and 5 0 -CATGTGGGCCATGAGGTC CACCAC-3 0 , producing a product of 982 bp. PCR products were visualized on 2% agarose gel with added ethidium bromide.
K-ras mutation analysis
Enriched PCR procedure was carried out using the method of Behn et al. (1998) .
